1)O'Connor KC, et al:Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 13:211-217, 2007 PMID 17237795
2)Sato DK, et al:Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82:474-481, 2014 PMID 24415568
3)Cobo-Calvo A, et al:Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults;The MOGADOR study. Neurology 90:e1858-e1869, 2018 PMID 29695592
4)Ogawa R, et al:MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm 4:e322, 2017 PMID 28105459
5)Banwell B, et al:Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease;International MOGAD Panel proposed criteria. Lancet Neurol 22:268-282, 2023 PMID 36706773
6)Nakamura M, et al:Epidemiological and clinical characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease in a nationwide survey. Mult Scler 29:530-539, 2023 PMID 36905136
7)Flanagan E, et al:The epidemiology of myelin oligodendrocyte glycoprotein antibody associated disorders. Mult Scler 25(Suppl.2):160, 2019
8)O'Connell K, et al:Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK. J Neurol Neurosurg Psychiatry 91:1126-1128, 2020 PMID 32576617
9)Orlandi R, et al:Prevalence, incidence, and season distribution of MOG antibody-associated disease in the province of Verona, Italy. Mult Scler Relat Disord 63:103884, 2022 PMID 35700669
10)Tan K, et al:Central nervous system inflammatory demyelinating diseases and neuroimmunology in Singapore—Epidemiology and evolution of an emerging subspecialty. Neurol Clin Neurosci 9:259-265, 2021
11)Hennes EM, et al:Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology 89:900-908, 2017 PMID 28768844
12)Jurynczyk M, et al:Clinical presentation and prognosis in MOG-antibody disease;A UK study. Brain 140:3128-3138, 2017 PMID 29136091